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Abstract: Nephrotoxicity is a dose limiting side effect associated with the use of cisplatin in the
treatment of solid tumors. The degree of nephrotoxicity is dictated by the selective accumulation of
cisplatin in renal tubule cells due to: (1) uptake by organic cation transporter 2 (OCT2) and copper
transporter 1 (CTR1); (2) metabolism by glutathione S-transferases (GSTs) and γ-glutamyltransferase
1 (GGT1); and (3) efflux by multidrug resistance-associated protein 2 (MRP2) and multidrug and toxin
extrusion protein 1 (MATE1). The purpose of this study was to determine the significance of single
nucleotide polymorphisms that regulate the expression and function of transporters and metabolism
genes implicated in development of acute kidney injury (AKI) in cisplatin treated patients. Changes
in the kidney function were assessed using novel urinary protein biomarkers and traditional markers.
Genotyping was conducted by the QuantStudio 12K Flex Real-Time PCR System using a custom open
array chip with metabolism, transport, and transcription factor polymorphisms of interest to cisplatin
disposition and toxicity. Traditional and novel biomarker assays for kidney toxicity were assessed for
differences according to genotype by ANOVA. Allele and genotype frequencies were determined
based on Caucasian population frequencies. The polymorphisms rs596881 (SLC22A2/OCT2), and
rs12686377 and rs7851395 (SLC31A1/CTR1) were associated with renoprotection and maintenance
of estimated glomerular filtration rate (eGFR). Polymorphisms in SLC22A2/OCT2, SLC31A1/CTRI,
SLC47A1/MATE1, ABCC2/MRP2, and GSTP1 were significantly associated with increases in the
urinary excretion of novel AKI biomarkers: KIM-1, TFF3, MCP1, NGAL, clusterin, cystatin C,
and calbindin. Knowledge concerning which genotypes in drug transporters are associated with
cisplatin-induced nephrotoxicity may help to identify at-risk patients and initiate strategies, such as
using lower or fractionated cisplatin doses or avoiding cisplatin altogether, in order to prevent AKI.
Keywords: cisplatin; nephrotoxicity; acute kidney injury; pharmacogenomics; CTR1; GGT1; GST;
KEAP1; MATE1; MRP2; NRF2; OCT2
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1. Introduction
While effective as a chemotherapeutic agent for various solid tumors [1–7], cisplatin has been
limited by its toxicities. Cisplatin treatment can result in nephrotoxicity, ototoxicity, neurotoxicity,
infections, and gastrointestinal toxicity secondary to its high emetogenic potential. Of these adverse
events, acute kidney injury (AKI) is a prominent toxicity. Approximately one-third of patients treated
with a single dose of cisplatin (50–100 mg/m2) will experience kidney impairment [8,9]. It is known
that cisplatin selectively accumulates in the proximal tubule, leading to oxidative stress, inflammation,
and vascular injury, and subsequent renal pathology [10]. The degree to which cisplatin and its
metabolites accumulate and induce injury can be influenced by the coordinated activity of uptake and
efflux transport proteins on the basolateral and apical membranes of the kidney proximal tubules [11].
Cisplatin metabolism is also important in governing proximal tubule exposure to the parent drug and
its conjugates [12].
Single nucleotide polymorphisms in cisplatin metabolism and transport genes are hypothesized
to modulate risk of nephrotoxicity. Uptake of cisplatin by kidney proximal tubule cells is governed
by organic cation transporter 2 (OCT2) [13] and copper transporter 1 (CTR1) [14] on the basolateral
membrane. Studies using mice lacking the Oct1 and -2 transporters have observed reduced kidney
exposure to cisplatin and attenuation of nephrotoxicity [13,15]. In the proximal tubule cell, cisplatin is
metabolized by glutathione S-transferase pi-1 (GSTP1) and γ-glutamyltransferase 1 (GGT1) enzymes.
The function of GST and GGT1 enzymes can also contribute to cisplatin induced nephrotoxicity [12].
Metabolism of cisplatin by GST results in a cisplatin-glutathione substrate that undergoes efflux
from the proximal tubule cell and is subsequently metabolized extracellularly at the apical brush
border membrane by GGT1 [12]. The resultant substrate, a cisplatin-cysteinyl-glycine conjugate,
is metabolized to cisplatin-cysteine by aminodipeptidase and reabsorbed into the proximal tubule
cell [12]. Subsequent metabolism processes in the proximal tubule cell lead to the development of
a reactive thiol that enhances nephrotoxicity [12]. This mechanism is supported by studies in mice
lacking GGT, showing protection against cisplatin induced kidney injury [16]. Cisplatin metabolites
are extruded from the proximal tubule cell into urine via brush border (apical) efflux transporters
including multidrug and toxin extrusion protein 1 (MATE1) and by multidrug resistance-associated
protein 2 (MRP2) [17]. MATE1- and MRP2-null mice display increased cisplatin induced kidney
toxicity and experience increased renal exposure to cisplatin [18,19]. Although knockout studies in
animals have supported genetic influences on cisplatin nephrotoxicity, there are limited studies to date
that have evaluated the role of genetics of metabolism enzymes and transporters on risk of cisplatin
nephrotoxicity in humans [20].
Regulatory proteins, such as Kelch-like ECH-associated protein 1 (KEAP1) and nuclear factor
(erythroid-derived 2)-like 2 (NRF2), can modulate the expression of metabolism and transport processes
including GSTs and MRP2 [21–23]. KEAP1 acts as a regulatory protein that represses the activity
of NRF2 and promotes its degradation by ubiquitination [24]. NRF2 is a transcription factor that
binds to antioxidant response elements (AREs) in the regulatory regions of target genes that direct
drug metabolism, transport, detoxification, and antioxidant function [21–23]. Mice lacking NRF2 are
reported to experience enhanced cisplatin nephrotoxicity, suggesting a role for NRF2 in protecting the
kidney [25].
Serum creatinine has been accepted as the clinical biomarker for determination of kidney function
and toxicity following cisplatin exposure. However, other novel protein biomarkers may be more
sensitive and specific markers of AKI [26]. Based on the current Kidney Disease Improving Global
Outcomes (KDIGO) Guidelines, AKI is defined by a rapid decline in kidney function based on
an increase of serum creatinine (≥0.3 mg/dL within 48 hours or ≥1.5 times baseline within the
previous seven days) and a decrease in urine output (<0.5 mL/kg/h for six hours) [27,28]. Compared
to traditional clinical markers, kidney injury molecule-1 (KIM-1), calbindin, trefoil factor 3 (TFF3),
and cystatin C are urinary biomarker candidates with enhanced sensitivity for assessing kidney injury
due to drugs such as cisplatin [29–32]. Relationships between urinary biomarkers, as indicators of
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cisplatin kidney injury, and polymorphisms in candidate drug metabolism and transport genes have
not previously been evaluated.
The current study sought to elucidate the influence of polymorphisms in drug transport,
metabolism, and regulatory genes on cisplatin-induced nephrotoxicity by assessing changes in novel
urinary protein biomarkers as subclinical measures of injury.
2. Results
2.1. Patient Characteristics
A total of 206 patients who were scheduled to receive or who had received cisplatin were
recruited. This included prospective (n = 57) and retrospective (n = 149) patients. For the prospective
patients, a subset (n = 28) were recruited prior to the first cycle of cisplatin-containing chemotherapy,
while another subset (n = 29) was recruited prior to the second cycle of cisplatin. The average time
between first and second dose was 17 days (range of 6–34 days). Prospective patients contributed
both genetics and urinary biomarker data, while retrospective patients contributed only genetics
data. All patients were adequately hydrated and were not exposed to any concomitant nephrotoxins.
Patient demographic and baseline laboratory characteristics are shown in Table 1 [33]. The commonly
co-prescribed (greater than 10%) chemotherapeutic agents included etoposide (n = 38, 18%), vinblastine
(n = 32, 16%), dacarbazine (n = 29, 14%), aldesleukin (n = 28, 14%), interferon alfa 2b (n = 27, 13%),
gemcitabine (n = 23, 11%), and docetaxel (n = 23, 11%). The allelic frequencies were in Hardy-Weinberg
Equilibrium (HWE) (Table 2). The expected frequencies of minor and major alleles used in the HWE
determinations were for the Caucasian (EUR) population in HapMap, which reflected the majority
(92%) of patients enrolled in the study.
Table 1. Patient Characteristics (n = 206).
Data Presented as Mean± Standard Deviation
Age 53 ± 14 years
BSA 1.9 ± 0.3 m2
Gender 51% male: 49% female
Weight 80 ± 20 kg
Race 92% White: 8% Other
First Cisplatin Dose 59 ± 25 mg/m2
Total Dose 479 ± 219 mg
Baseline Serum Creatinine 0.9 ± 0.2 mg/dL
Baseline eGFR 91 ± 21 mL/min/1.73 m2
Cancer Etiologies (number, %)
Genital (54, 26%)
Head and Neck (41, 20%)
Melanoma (31, 15%)
Lung (25, 12%)
Digestive (21, 10%)
Urinary (18, 9%)
Other (16, 8%)
Abbreviations: Body surface area: BSA; Estimated glomerular filtration rate: eGFR.
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Table 2. Genotype and Allelic Frequencies for Transport, Metabolism, and Regulatory Genes Relevant to Cisplatin Disposition (n = 206).
Gene Variant Homozygous WildtypeFrequency Observed
Heterozygous
Frequency Observed
Homozygous Variant
Frequency Observed Undeter-Mined
Major Allele Frequency
Observed (Expected)
Minor Allele Frequency
Observed (Expected)
SLC22A2
(OCT2)
rs316019 * C/C 0.679 A/C 0.187 A/A 0.014 0.120 C 0.824 (0.79) A 0.118 (0.21)
rs3127573 A/A 0.737 A/G 0.211 G/G 0.010 0.043 A 0.858 (0.88) G 0.10 (0.12)
rs2279463 A/A 0.665 A/G 0.201 G/G 0.005 0.014 A 0.869 (0.88) G 0.097 (0.12)
rs596881 C/C 0.741 C/T 0.230 T/T 0.010 0.019 C 0.861 (0.89) T 0.098 (0.11)
SLC31A1
(CTR1)
rs7851395 A/A 0.306 A/G 0.431 G/G 0.187 0.077 A 0.553 (0.53) G 0.431 (0.47)
rs12686377 C/C 0.718 A/C 0.158 A/A 0.038 0.086 C 0.847 (0.92) A 0.194 (0.08)
SLC47A1
(MATE1) rs2289669 G/G 0.278 A/G 0.464 A/A 0.196 0.062 G 0.527 (0.54) A 0.443 (0.46)
ABCC2
(MRP2)
rs717620 C/C 0.603 C/T 0.258 T/T 0.043 0.096 C 0.776 (0.81) T 0.207 (0.19)
rs2273697 * G/G 0.531 A/G 0.325 A/A 0.053 0.091 G 0.729 (0.82) A 0.23 (0.18)
rs3740066 C/C 0.397 C/T 0.368 T/T 0.144 0.091 C 0.63(0.62) T 0.379 (0.38)
GGT1 rs4820599 A/A 0.464 A/G 0.349 G/G 0.100 0.086 A 0.681 (0.73) G 0.316 (0.27)
GSTP1 rs1695 * A/A 0.354 A/G 0.402 G/G 0.129 0.033 A 0.63(0.59) G 0.372 (0.41)
KEAP1
rs11085735 C/C 0.746 A/C 0.139 A/A 0.014 0.100 C 0.864 (0.91) A 0.118 (0.09)
rs1048290 C/C 0.282 C/G 0.407 G/G 0.129 0.182 C 0.531 (0.68) G 0.359 (0.32)
NFE2L2
(NRF2)
rs2886162 A/A 0.239 A/G 0.459 G/G 0.220 0.081 A 0.489 (0.58) G 0.469 (0.42)
rs1806649 C/C 0.512 C/T 0.311 T/T 0.053 0.124 C 0.716 (0.77) T 0.23 (0.23)
rs1962142 G/G 0.000 A/G 0.670 A/A 0.244 0.086 G 0(0.92) A 0.494 (0.08)
rs2706110 C/C 0.560 C/T 0.344 T/T 0.086 0.010 C 0.748 (0.8) T 0.293 (0.2)
rs6721961 G/G 0.665 G/T 0.225 T/T 0.024 0.091 G 0.815 (0.8) T 0.155 (0.2)
* Denotes non-synonymous variant.
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2.2. Associations between SLC22A2 and SLC31A1 Variants and Estimated Glomerular Filtration Rate (eGFR)
in Patients Receiving Cisplatin
Relationships between clinical kidney injury and polymorphisms in transporter, metabolism,
and regulatory genes were assessed using estimated glomerular filtration rate (eGFR), a standard
clinical measure of kidney function and overt nephrotoxicity. Genetic variants in the two cisplatin
uptake transporters SLC22A2 (OCT2) and SLC31A1 (CTR1) were associated with preservation of
kidney function. Patients with the CT genotype in SLC22A2 polymorphism rs596881 exhibited positive
changes in eGFR compared to individuals with the wildtype CC genotype (Figure 1A, p = 0.01).
Similarly, increases in eGFR were observed in patients with both SLC31A1 variants (rs12686377 and
rs7851395). Patients with the GG (rs12686377) and AA (rs7851395) variant genotypes had positive
changes in eGFR (p = 0.01 and p = 0.04) compared to patients with the wildtype genotypes AA
and CC, respectively (Figure 1B,C). Taken together, these data support renoprotective properties for
some genetic variants in cisplatin uptake transporters. By comparison, genetic variants for the efflux
transporters SLC47A1 and ABCC2 or metabolism genes GGT1 and GSTP1 were not associated with
changes in eGFR.
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genotypes on eGFR in ambulatory cancer patients prescribed cisplatin. Homozygous variant patients 
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Figure 1. (A) Comparisons of SLC22A2 (rs596881) genotypes on eGFR in ambulatory cancer patients
prescribed cisplatin. Patients carrying a variant allele of rs596881 in SLC22A2 exhibited statistically
significant increases in eGFR (p = 0.01). (B,C) Comparisons of SLC31A1 (rs12686377 and rs7851395)
genotypes on eGFR in ambulatory cancer patients prescribed cisplatin. Homozygous variant patients
for SLC31A1 (rs12686377 and rs7851395) exhibited eGFR protection with cisplatin therapy (p = 0.01 and
p = 0.04). Graphs indicate percent changes in eGFR from baseline. Abbreviations: Estimated glomerular
filtration rate: eGFR, Wildtype: WT, Variant: VAR.
Interestingly, patients with the CG genotype for a KEAP1 variant (rs1048290) had an increase
in eGFR compared to wildtype CC patients (p = 0.03). In addition, patients with the GG variant
(rs2886162) in the redox sensor NFE2L2 exhibited eGFR improvement relative to wildtype AA patients
(p = 0.04).
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2.3. Associations between Transporter Gene Variants and Novel Urinary Biomarkers of Kidney Injury in
Patients Receiving Cisplatin
Associations between transporter gene polymorphisms and novel urinary biomarkers generally
suggested that variant alleles were predictive of increases in the urinary excretion of kidney injury
biomarkers in patients receiving cisplatin, although there were a few notable exceptions (Table 3).
Significant changes in urinary biomarker excretion were associated with the uptake transporter genes
SLC22A2 and SLC31A1. Patients with the AC genotype for the SLC22A2 rs316019 polymorphism
exhibited higher urinary fold changes in KIM-1 at baseline (p = 0.02), Day 3 (p = 0.03), and Day 10
(p = 0.046) compared to the wildtype CC genotype (Figure 2, Table 3). Patients with a CT genotype in
the SLC22A2 variant rs596881 were also associated with a significant decrease in β2 microglobulin
(B2M) and increase in osteopontin at Day 3 after cisplatin relative to patients with the wildtype CC
genotype (Table 3). It should be noted that patients expressing two copies of the variant alleles for the
rs316019 and rs596881 variants in SLC22A2 did not exhibit significant changes in urinary biomarkers
due to their small numbers (n = 3 rs316019 and n = 1 rs596881). In addition to SLC22A2, a positive
association between SLC31A1 and a urinary biomarker was observed. Patients with the GG variant
in rs7851395 had greater increases in urinary osteopontin levels at Day 3 after cisplatin treatment
(Table 3).
Table 3. Associations between Variant Genotypes and Fold Change Increases in Urinary Biomarkers of
Kidney Injury (n = 57) *.
Gene Variant ProteinBiomarker Time
Fold Change
(WT/WT vs. WT/Var) p-value
Fold Change
(WT/WT vs. Var/Var) p-value
SLC22A2
(OCT2)
rs596881
B2M Day 3 −2.134 0.039 2.474 0.057
Osteopontin Day 3 1.918 0.049 −1.052 0.972
rs316019
KIM-1 Day 3 1.77 × 10171 0.038 N/A N/A
KIM-1 Day 10 −1.38 × 1084 0.046 N/A N/A
SLC31A1
(CTR1) rs7851395 Osteopontin Day 3 1.341 0.488 2.509 0.015
SLC47A1
(MATE1) rs2289669
KIM-1 Day 3 1.379 0.636 3.605 0.007
MCP-1 Day 3 1.322 0.629 2.952 0.015
ABCC2
(MRP2)
rs717620
Clusterin Day 3 3.534 0.024 −2.981 0.854
Cystatin C Day 3 2.627 0.034 1.279 0.910
rs3740066
Calbindin Day 3 1.900 0.017 1.068 0.883
Calbindin Day 10 2.732 0.023 −1.269 0.822
Clusterin Day 3 1.170 0.870 4.384 0.012
Cystatin C Day 3 1.601 0.447 3.094 0.038
NGAL Day 3 2.110 0.030 1.011 0.986
rs2273697
KIM-1 Day 3 1.153 0.730 5.966 4.29 × 10−5
KIM-1 Day 10 1.163 0.636 2.808 0.042
Calbindin Day 3 1.124 0.687 2.648 0.038
MCP-1 Day 3 −1.215 0.635 3.500 0.010
GSTP1 rs1695
KIM-1 Day 3 1.195 0.732 2.690 0.029
Calbindin Day 3 1.369 0.354 2.371 0.012
IL-18 Day 10 −1.566 0.337 2.287 0.012
NGAL Day 3 1.294 0.572 2.569 0.027
KEAP1
rs1048290 NGAL Day 3 −1.849 0.211 2.051 0.035
rs11085735
Calbindin Day 10 2.944 0.019 −17.366 0.661
Cystatin C Day 3 3.275 0.011 1.207 0.928
Cystatin C Day 10 2.600 0.027 −2.481 0.751
TFF3 Day 3 1.747 0.038 1.466 0.619
TFF3 Day 10 1.776 0.034 −1.629 0.685
NFE2L2
rs2886162 Calbindin Day 10 3.486 0.029 1.53 0.710
rs1806649
IL-18 Day 3 −1.298 0.692 3.744 0.002
TFF3 Day 3 −1.133 0.709 2.337 0.004
rs1962142 TFF3 Day 10 −1.638 0.028 N/A N/A
rs2706110 MCP-1 Day 10 1.236 0.621 3.182 0.002
* Only significant figures included. Abbreviations: β-2 microglobulin: B2M; Glutathione-s-transferase pi 1: GSTP1;
Interleukin 18: IL-18; Kidney Injury Molecule 1: KIM-1; Monocyte chemotactic protein 1:MCP-1; Neutrophil
gelatinase-associated lipocalin: NGAL; Trefoil factor 3: TFF3; Variant: VAR; Wildtype: WT.
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Figure 2. (A) Comparison of absolute KIM-1 concentrations by SLC22A2 (rs316019) genotype in
ambulatory cancer patients prescribed cisplatin. Statistically significant increases of KI -1 at baseline
(p = 0.02), Day 3 (p = 0.03), and Day 10 (p = 0.046) ere de onstrated in patients expressing the
SLC22A2 rs316019 variant. (B) Co parison of absolute KI -1 concentrations to ABCC2 (rs2273697)
genotype in a bulatory cancer patients prescribed cisplatin. Statistically significant increases of KIM-1
at baseline (p = 0.02), Day 3 (p = 0.03) and ay 10 (p = 0.046) ere de onstrated in patients expressing
the 2 rs2273697 variant. rror bars re resent stan ar eviations. bbreviations: i ney inj ry
lec le 1: I -1, il t e: , aria t: ar.
The AA genotype for the rs2289669 variant in the SLC47A1 gene was associated with fold
change elevations in KIM-1 (p = 0.007) and monocyte chemoattractant protein-1 (MCP-1, p = 0.015)
at Day 3 after cisplatin administration compared to patients with the wildtype GG genotype. In
addition, variants in the ABCC2 gene were predominantly associated with higher concentrations of
AKI-associated urinary biomarkers. The ABCC2 variant rs3740066 was associated with enhanced
calbindin levels in urine after cisplatin administration. Calbindin concentrations were significantly
elevated by 2.2-, 1.9-, and 2.7-fold at baseline, Day 3, and Day 10, respectively, in variant (TT vs. CC)
genotype patients (Table 3, Figure 3). The ABCC2 rs3740066 polymorphism was also associated with
statistically significant increases in the urinary excretion of clusterin, cystatin C, and NGAL at Day 3
(Table 3). In addition to the rs3740066 variant, patients with the CT genotype for the rs717620 ABCC2
variant exhibited a 3.5-fold increase in clusterin and 2.6-fold enhancement of cystatin C concentrations
at Day 3 compared to the wildtype CC genotype (Table 3). Few patients were homozygous for the
rs3740066 and rs717620 variants in ABCC2 and, in turn, no significant associations were observed with
the excretion of urinary biomarkers following cisplatin treatment.
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0.027) (Table 3). Elevations in TFF3 were 2.5-, 1.8-, and 1.8-fold in patients with the AC genotype for 
rs11085735 compared to wildtype CC individuals at baseline, Day 3, and Day 10, respectively (p = 
0.006, p = 0.038, p = 0.034) (Table 3). There were limited numbers of patients with the AA genotype 
for the rs11085735 polymorphism in KEAP1; in turn, no significant associations were observed with 
urinary biomarkers. 
i r . o parison of c l i in s l te tratio s t (r ) t i
a lat r ca cer patients prescribed cisplatin. Absolute concentrations of calbindin were elevated in
patients with t e variant allele at all time points; statistically significant at baseline (p = 0.047), Day 3
(p = 0.02), and Day 10 (p = 0.02) versus ho ozygous ildtype patients. Error bars represent standard
deviations. bbreviations: ild type: T, ariant: ar.
f i j i
Patients Receiving Cisplatin
Patients ith the genotype for the GSTP1 rs1695 variant had significant elevations in urinary
bio arkers indicative of I co pared to ildtype patients. They exhibited t o-fold or greater
increases in urinary KI -1, calbindin, and NGAL concentrations at Day 3 and urinary IL-18 at Day 10
(Table 3).
2.5. Association between Regulatory Genes and Novel Urinary Biomarkers of Kidney Injury in Patients
Receiving Cisplatin
A few of the evaluated NFE2L2 variants were associated with significant fold changes in the
excretion of urinary biomarkers. Homozygous variants of NFE2L2 rs1806649, rs1962142, rs2886162,
and rs2706110 were associated with statistically significant fold-change increases in IL-18, TFF3,
calbindin, and MCP-1, respectively, versus homozygous wildtypes (Table 3).
The KEAP1 polymorphism rs11085735 was associated with the excretion of several urinary
biomarkers in patients who were heterozygous versus homozygous wildtype. Cystatin C and TFF3
fold changes were statistically increased on Day 3 and Day 10 in patients with the AC variant genotype
compared to wildtype CC patients (Table 3, Figure 4). Cystatin C concentrations on Day 3 and Day
10 were enhanced by 3.3- and 2.6-fold, respectively, in patients with at least one copy of the KEAP1
rs11085735 variant (AC) compared to patients with the reference alleles (CC) (p = 0.011, p = 0.027)
(Table 3). Elevations in TFF3 were 2.5-, 1.8-, and 1.8-fold in patients with the AC genotype for rs11085735
compared to wildtype CC individuals at baseline, Day 3, and Day 10, respectively (p = 0.006, p = 0.038,
p = 0.034) (Table 3). There were limited numbers of patients with the AA genotype for the rs11085735
polymorphism in KEAP1; in turn, no significant associations were observed with urinary biomarkers.
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3. Discussion
The current study sought to address the role of variants in drug transport, metabolism, and
regulatory genes on cisplatin-induce nephrotoxicity in cancer patients by assessing changes in the
urinary concentrations of novel protei biomarkers as m rk rs of subclinical injury to the kid eys.
The results d monstrate associations that support the role of transporter and metabolizing enzyme
genetics on risk or mitig ti n of risk of kidney injury by cisplatin. While specific variants in the
uptake tra sporters SLC22A2 (rs596881) an SLC31A1 (rs12686377 and rs7851395) were associated
with preserved eGFR, respectively, other variants in these genes were associated with fold-changes
in novel urinary biomarkers. Variants in the efflux transporter genes ABCC2 and SLC47A1 were
associated with elevations in novel urinary biomarkers, but n t eGFR. The SLC47A1 variant rs2289669
correlate with enhanced KIM-1 and MCP-1 concentrations. Significantly higher levels of KIM-1 at
Day 3 were observed in patients with the ABCC2 variant rs2273697. The ABCC2 rs3740066 variant
was associated with consistently enhanced fold-c anges in calbindin, cystatin C, clusterin, and NGAL
in patients who carrie one or two alleles. Patients who carried the varia ts in rs1695 (GSTP1) have
higher urinary concentrati ns of several biomarkers including KIM-1, calbindin, NGAL, a d IL-18.
Lastly, since regulatory genes such as NFE2L2 and KEAP1 can indirectly influence the effects of
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transporter and drug metabolizing enzyme genes [34,35], associations between polymorphisms
in these genes and novel urinary biomarkers were also evaluated. The NFE2L2 polymorphism
rs2886162 was consistently associated with enhanced calbindin excretion from baseline, while the
KEAP1 polymorphism rs11085735 was associated with increases in TFF3 and cystatin C concentrations.
The current study is the first report to date in a cisplatin-treated patient cohort that has evaluated
associations between targeted pharmacogenomics of drug transport and metabolism genes and a panel
of novel urinary biomarkers of kidney injury. A follow-up validation study will be needed to confirm
the findings from the current study.
The importance of the OCT2 uptake transporter in cisplatin renal clearance was previously
reported in a study employing Oct1/2 mouse knockouts [20]. These authors subsequently evaluated
changes to serum creatinine after treatment with cisplatin in human cancer patients (n = 78) according
to the presence or absence of a copy of the nonsynonymous SLC22A2 rs316019 variant denoting reduced
OCT2 function [20]. The presence of the SLC22A2 variant was associated with maintenance of serum
creatinine. The SLC22A2 polymorphism rs316019 (G808T; Ser270Ala) has also been associated with
protection from cisplatin ototoxicity [36], odds of hepatotoxicity and hematologic toxicity secondary to
platinum chemotherapy [37], and increased metformin renal and secretory clearance [38]. In the current
study, patients heterozygous vs. homozygous wildtype for the SLC22A2 rs316019 polymorphism had
associated higher concentrations and fold-changes in urinary KIM-1 at baseline, Day 3, and Day 10 as
compared to wildtype homozygotes. The SLC22A2 rs596881, rs3127573, and rs2279463 variants were
associated with elevations in B2M at Day 3. In addition, in the current study, patients with the SLC22A2
rs596881 variant exhibited a preservation of eGFR. A prior study has associated the SLC22A2 rs3127573
variant with increased OCT2 function [39]. Based on our data and the supporting literature, variants
in the SLC22A2 gene were related to risk or mitigation of risk for cisplatin induced kidney injury.
A previous study has reported on a genetic variant (rs10981694) in the copper transporter protein
1 (SLC31A1) and cisplatin-induced ototoxicity [40]. An additional study observed increased platinum
resistance in lung cancer patients that was associated with two SLC31A1 variants (rs7851395 and
rs12686377) [41]. The current study reported significant fold increases in eGFR in homozygous variant
versus homozygous wildtype patients (p = 0.01 and p = 0.04) with the previously reported variants
(rs12686377 and rs7851395) in the SLC31A1 gene. We also found higher osteopontin concentrations
associated with homozygosity for the SLC31A1 variant rs7851395 at Day 3 post cisplatin treatment.
These studies support the role of CTR1 variants on protection from changes in kidney function (eGFR),
but the increase in osteopontin at Day 3 post cisplatin may reflect subacute injury prior to the later
improvement in eGFR.
The transporters MATE1 and MRP2 are brush border proteins that efflux cisplatin from
proximal tubule cells to urine and reduce the susceptibility to nephrotoxicity [18,19]. A previous
publication noted that the SLC47A1 rs2289669 variant was linked to hematological toxicity secondary
to platinum containing chemotherapy [37]. Using oxaliplatin as a substrate, an in vitro study with
SLC47A1-transfected variants in HEK-293 cells demonstrated loss of MATE1 function [42]. Several
publications have reported on variants in SLC47A1 and the pharmacokinetics and pharmacodynamics
of metformin [43–46]. The presence of the SLC47A1 polymorphism rs2289669 resulted in higher area
under the plasma concentration time curve and lower renal clearance of metformin [44]. In the current
study, the SLC47A1 rs2289669 variant was correlated with increases in the urinary biomarkers KIM-1
and MCP-1. Decreased function polymorphisms in SLC47A1 are important for potentially increasing
therapeutic efficacy, reducing renal clearance, and enhancing kidney toxicity of pharmaceutical
substrates of MATE1.
Polymorphisms in the ABCC2 gene have been shown to affect medication efficacy and safety.
Variants in the ABCC2 gene have been purported to influence the therapeutic efficacy of anti-epileptic
drugs [47–50]. Other studies have identified an association between variants in the ABCC2 gene and
tenofovir induced kidney tubular dysfunction [51]. The ABCC2 rs717620 variant has previously been
linked with responses to platinum chemotherapy [37]. However, in cancer patients, one study failed to
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demonstrate a relationship between polymorphisms in ABCC2 and cisplatin pharmacokinetics, which
may be due to low statistical power or the use of traditional AKI endpoints [52]. In the current study,
several ABCC2 variants were correlated with increased urinary biomarkers of AKI in patients receiving
cisplatin; however, no relationships were observed with eGFR.
Significantly greater increases in urinary calbindin, clusterin, cystatin C, and NGAL at Day 3,
and calbindin at Day 10 were observed in ABCC2 variant rs3740066. Patients heterozygous for the
ABCC2 variant rs717620 exhibited increases in clusterin (3.5-fold) and cystatin C (2.6-fold) at Day 3.
The current study in patients receiving cisplatin chemotherapy and published data from patients with
epilepsy and HIV-1 support the influence of polymorphisms in ABCC2 on biomarker changes and
outcomes such as efficacy and toxicity.
Glutathione S-transferases metabolize platinum chemotherapeutics including cisplatin.
The GSTP1 Ile105Val polymorphism was previously purported to be associated with less
neuropathy [53] and clinical outcomes [54] related to oxaliplatin. The current study reported
associations in the same GSTP1 variant (rs1695) and significant increases in the urinary biomarkers
KIM-1, Calbindin, and NGAL at Day 3 and IL-18 at Day 10 after cisplatin chemotherapy. While
polymorphisms in GST metabolism genes appear to have some significance with biomarker changes,
further study is required to fully evaluate the influence of metabolism in the presence or absence of
transporter haplotypes.
It is known that regulatory genes such as NFE2L2 and KEAP1 can influence the expression and
function of transporters and drug metabolizing enzymes [34,35]. A previous publication reported
a relationship between a promoter variant in NFE2L2 and susceptibility to ototoxicity with high
cumulative doses of cisplatin [55]. The current study found links between NFE2L2 polymorphisms
and the enhanced excretion of urinary AKI biomarkers. The NFE2L2 polymorphism rs2886162 was
related to increases in calbindin at Day 10 vs. homozygous wildtypes. Additionally, homozygous
variants of NFE2L2 polymorphisms rs1806649, rs1962142, rs2886162, and rs2706110 were correlated
with statistically significant fold-change increases in IL-18, TFF3, MCP-1, and cystatin C. Because
KEAP1 is related to NRF2, polymorphisms in KEAP1 were also evaluated for their relationships with
urinary biomarkers. TFF3 and cystatin C levels were statistically increased on Day 3 and Day 10 vs.
homozygous wildtype patients for KEAP1 (rs11085735). The interaction between polymorphisms
involved in cisplatin regulation, metabolism and transport has the potential to clarify mechanisms of
cisplatin induced kidney injury.
The strength of the study lies in the comprehensive and targeted genomic approach to evaluating
cisplatin induced kidney injury based on the hypotheses that genomics of drug transport and
metabolism are a central component of this toxicity. This study incorporated polymorphisms involved
in both processes as well as in regulation of these processes. Additionally, the current study evaluated
kidney injury using both traditional measures and a panel of novel urinary biomarkers. However,
several limitations exist for this study. This study was primarily comprised of Caucasian patients,
which reduces its generalizability to other races. Due to the limited number of non-Caucasian
races, genotype frequency data (Table 2) were assessed based on the published data for Caucasians.
The patients in the study received low to moderate doses of cisplatin, potentially limiting our ability to
detect clinical nephrotoxicity (as evidenced by elevations in serum creatinine) and associations between
urinary biomarkers and pharmacogenetic variants. While the current study assessed relationships
between genomics of selected drug metabolism and transport genes important for the disposition
of cisplatin, the role of these polymorphisms in other forms of drug induced kidney injury may not
be directly applicable and requires further study. This study was also not designed to study cancer
specific outcomes such as progression free or overall survival based on genotype.
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4. Materials and Methods
4.1. General Reagents
FlexiGene® DNA Kits (ID# 51206) for DNA extraction from blood were purchased from QIAGEN
Inc. (Germantown, MD, USA). Calbindin, clusterin, KIM-1, GST-P1, IL-18, MCP-1, albumin, B2M,
cystatin C, NGAL, osteopontin, and TFF3 assays (Bio-Plex Pro RBM human kidney toxicity assay
panels 1 and 2) were purchased from Bio-Rad, Life Science (Hercules, CA, USA).
4.2. Study Population
Eligible patients were greater than 18 years old and were treated with intravenous cisplatin for
treatment of solid tumors in outpatient clinics at the University of Colorado Cancer Center, Aurora, CO,
a National Cancer Institute–Designated Consortium Comprehensive Cancer Center. Patients received
intravenous cisplatin in doses of ≥20 mg/m2. Other inclusion criteria were hemoglobin ≥10 g/dL,
no consumption of grapefruit juice or alcohol within 7 days, no history of alcohol consumption
of >14 drinks/week, no history of organ transplantation or kidney dialysis, willingness to comply
with study, not pregnant or lactating, no changes in medications within previous 4 weeks, and normal
liver function (ALT and AST <2 times ULN). As part of the standard of care protocol, patients were
hydrated with 0.9% sodium chloride (1–2 L) pre- and post-cisplatin infusion. Exclusion criteria
included a diagnosis of kidney cancer, previous exposure to platinum-based chemotherapy, herbal
supplement use, exposure to other known nephrotoxins (including contrast agents) within previous
30 days, and concurrent use of inhibitors of cisplatin transport proteins.
Blood was collected for DNA isolation from patients who were either scheduled to receive cisplatin
prospectively or had historically received cisplatin treatment. Patient demographics (e.g., race, age,
gender, weight, body surface area), pre-chemotherapy laboratory tests (e.g., serum creatinine, estimated
glomerular filtration rate [33], blood urea nitrogen, urinary albumin excretion, electrolytes, liver
function tests, and complete blood count), medical and medication history, and physical examination
data were collected.
The Institutional Review Boards at the University of Colorado (COMIRB Protocol 12-1510) and
Rutgers University (Protocol E13-716) approved protocols for recruitment and sample collection.
The investigations were carried out in accordance with the rules of the Declaration of Helsinki [56].
4.3. DNA Isolation
Blood (5 mL) was collected in heparinized tubes from recruited patients who were scheduled
to receive or had historically received cisplatin therapy. Whole blood underwent centrifugation at
2500× g for 10 minutes at room temperature to obtain buffy coats for DNA extraction. Resultant buffy
coats were aliquoted into 1.5 mL tubes and frozen at −80 ◦C until DNA isolation. DNA from buffy
coats was extracted and purified per FlexiGene® DNA Handbook (QIAGEN) protocol and stored in a
stock concentration of 20 ng/mL. DNA was stored at −80◦C until subsequent genotyping.
4.4. Genotyping
Genotyping was performed using QuantStudio 12K Flex Real-Time PCR System at the University
of Utah Genomics Core Facility. Custom Open Array Chips (Thermo Fisher Scientific, Waltham, MA,
USA) were designed with selected polymorphisms of interest including transporters (e.g., SLC22A2,
ABCC2, SLC47A1), regulatory (e.g., NFE2L2 and KEAP1) and metabolism (e.g., GSTA1, GSTP1, and
GGT1) genes. For the Chip, DNA primer sequences were created based on polymorphism ID from
NCBI polymorphism Database. Taqman Genotype Software was used to code each genotype as 0
for homozygous wildtypes (wildtype/wildtype), 1 for heterozygous (wildtype/variant), and 2 for
homozygous variants (variant/variant) in order to perform statistical analyses.
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4.5. Collection of Urine Samples
Urine samples for protein biomarkers were obtained from all patients who were prospectively
scheduled to receive cisplatin treatment. Urine samples were collected at baseline (pre-infusion or
at 0–2 h after infusion), between 2–5 days (denoted as Day 3) and 9–11 days (designated as Day 10)
post-cisplatin infusion. Urine was centrifuged at 3000× g and the supernatant was aliquoted for
subsequent biomarker assays. All samples were frozen at−80 ◦C within 30–60 min following collection.
At time of analysis, samples were thawed, placed on ice and centrifuged at 1500 rpm for 5 min. Ten µL
of supernatant was used for biomarker analyses.
4.6. Assessment of Urinary Biomarkers
Urinary samples for protein biomarkers (e.g., calbindin, clusterin, KIM-1, GST-pi, IL-18, MCP-1,
albumin, B2M, cystatin C, NGAL, osteopontin, TFF3) were washed using a Bio-Plex Pro II wash
station (Bio-Rad) and then analyzed using Bio-Plex, MagPix Multiplex Reader (Bio-Rad). The resultant
mean fluorescence intensity (MFI) was used to calculate respective concentrations of each biomarker
in the sample. Analysis was completed per protocol with dilutions of 1:10 for panel 1 and 1:50 for
panel 2. When concentrations fell outside of the detection limit of the assay, they were diluted and
re-analyzed or substituted with the lower limit of quantification divided by 2. The eGFR was obtained
from the medical record at baseline and after the first cisplatin dose and calculated using the CKD-EPI
equation [33]. Additional details on biomarker analysis methods was previously published [57].
Biomarker data was not normalized to urinary creatinine as our previous study demonstrated similar
findings with absolute and normalized data [57]. Biomarker data was assayed at baseline, and Day 3
and Day 10 post cisplatin administration.
4.7. Statistical Analysis
Patient demographic data includes the group mean ± standard deviation. Hardy Weinberg
equilibrium was used to analyze allelic frequencies by Chi Square Tests. Differences in eGFR or
biomarker changes by genotype groups were evaluated by Students T-test or ANOVA with Dunn’s
multiple comparisons post hoc test. Differences were considered statistically significant at p < 0.05.
Due to the pilot and hypothesis generating nature of the research and the limited sample of patients
who had matched genomics and urinary biomarker data, we did not apply any FDR adjustments on
p values. Patients with missing values were excluded from analysis. All statistical analyses and graphs
were completed by GraphPad Prism V6 (GraphPad Software, La Jolla, CA, USA), Partek Genomics
Suite (Partek GS 6.4, St. Louis, CA, USA), and SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
5. Conclusions
An improved understanding of the role of pharmacogenetic variants that regulate cisplatin
transport and metabolism in renal tubule cells may help to reduce the severity of kidney injury and
prevent morbidity in patients receiving treatment with cisplatin. The current study facilitates a greater
understanding of the influence a patient’s genotype contributes toward nephrotoxic risk in order
to potentially inform about a preemptive screen to reduce the risk of kidney damage. Knowledge
concerning which polymorphisms are associated with cisplatin induced nephrotoxicity will help to
stratify patients at greatest risks to integrate strategies to prevent AKI and improve treatment outcomes
in cancer patients.
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